January 2017 Annual Meeting Edition
Volume 3, Issue 2
This issue features expanded coverage of the 2016 ASH Annual Meeting, as well as a focus on CAR T-cell therapy, and more.
Table of Contents
January 2017 Annual Meeting Issue
The Family That Puzzles Together …
In December’s issue, Associate Editor David Steensma, MD, shared his lifelong love of word games, and how he went from fighting over the newspaper...
January 2017 Annual Meeting Issue
ASH Medical Educators Institute, New ASH On Demand Webinars, and more
ASH Emphasizes the Importance of Medical Education Careers With ASH MEI
The American Society of Hematology (ASH) Medical Educators Institute (MEI) is designed to develop...
ASH Recognizes Choosing Wisely® Champions, NIH Awards Grant to Examine Spliceosomal Mutations in MDS,...
ASH Recognizes Choosing Wisely® Champions During Annual Meeting
The American Society of Hematology (ASH) recognized three inaugural Choosing Wisely® Champions during the 2016 annual meeting....
January 2017 Annual Meeting Issue
Cartwheels for CAR T-Cell Therapy?
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach to targeted immunotherapy to treat cancer, and the details can seem like the stuff...
January 2017 Annual Meeting Issue
Uncovering the Natural History of Primary Ocular Adnexal MALT Lymphoma
Primary ocular adnexal MALT lymphoma (POAML) is the most common orbital tumor affecting patients in the United States, but little is known about the...
Characterizing Ph-Like Acute Lymphocytic Leukemia: A High-Risk Subgroup With Few Treatment Options
Treatment outcomes of patients with B-cell acute lymphocytic leukemia (B-ALL) vary according to age, with adult patients experiencing a poorer prognosis than pediatric patients....
CMS Experimenting With New Accountable Care Organization Model, FDA Updates, and more
CMS Experimenting With New Accountable Care Organization Model
The Centers for Medicare & Medicaid Services (CMS) announced the Medicare−Medicaid Accountable Care Organization (ACO) Model, which...
Enoxaparin Does Not Prevent Placenta-Mediated Complications in Pregnant Women With Severe Preeclampsia
Pregnant women who have severe preeclampsia (a disease characterized by impaired vascular response to placentation) before 34 weeks of pregnancy are at an increased...
Randomized Trial Finds Rivaroxaban a Safer Option Than Warfarin for Patients With Atrial Fibrillation...
The “triple-therapy” anticoagulation regimen (consisting of a vitamin K antagonist plus dual antiplatelet therapy with a P2Y12 inhibitor and aspirin) has been...
January 2017 Annual Meeting Issue
Balancing Bleeding and Thrombosis Risk With Anticoagulation in Patients With Hematologic Malignancies and Thrombocytopenia
Two studies presented at the 2016 ASH Annual Meeting examined the safety of anticoagulation therapy in patients with hematologic malignancies – a population with...
Results from Phase III SWOG Trial: 7+3 Still the Standard of Care for Patients...
Remission induction with 7+3 chemotherapy (cytarabine + daunorubicin) should remain the standard of care for younger patients with acute myeloid leukemia (AML), according to...
Subcutaneous Delivery of Daratumumab Is Safe, Effective in Multiple Myeloma
While daratumumab was approved by the U.S. Food and Drug Administration (FDA) as an intravenous (IV) infusion for the treatment of multiple myeloma (MM),...
Large Registry Analysis Confirms Autologous Hematopoietic Cell Transplantation Is Feasible in Older Patients
Older patients (≥65 years) with hematologic malignancies are often considered unsuitable for autologous hematopoietic cell transplantation (AHCT) because of the potential for higher risks...
A Life-Saving, Multidisciplinary Approach to Treating Pregnant Women With Sickle Cell Disease in Ghana
Pregnant women with sickle cell disease (SCD) living in Ghana have a high maternal mortality rate of 8,300 deaths per 100,000 live births –...
Living Longer, Living Better: Looking at Health-Related Quality of Life With Maintenance Therapy in...
Although randomized trials have shown that long-term maintenance therapy can prolong survival in patients with multiple myeloma (MM) who have undergone autologous hematopoietic transplantation...
